Viking Therapeutics (VKTX) Earnings Date, Estimates & Call Transcripts $42.25 +0.76 (+1.83%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Viking Therapeutics Latest Earnings SummaryActual EPS (Oct. 23) -$0.22 Beat By $0.02 Consensus EPS (Oct. 23) -$0.24 Viking Therapeutics announced Q3 2024 earnings on October 23, 2024, reporting an EPS of -$0.22, which beat the consensus estimate of -$0.24 by $0.02. With a trailing EPS of -$0.93, Viking Therapeutics' earnings are expected to decrease next year, from ($0.97) to ($1.34) per share. Conference CallConference Call TranscriptPowered by Get Viking Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Viking Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataVKTX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.VKTX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Viking Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20243-$0.27-$0.25-$0.26Q2 20243-$0.28-$0.17-$0.24Q3 20243-$0.29-$0.23-$0.26Q4 20244-$0.27-$0.24-$0.25FY 202413-$1.11-$0.89-$1.01Q1 20252-$0.29-$0.28-$0.29Q2 20252-$0.30-$0.28-$0.29Q3 20252-$0.32-$0.30-$0.31Q4 20252-$0.32-$0.29-$0.31FY 20258($1.23)($1.15)($1.19) Viking Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails10/23/2024Q3 2024-$0.24-$0.22+$0.02-$0.22--7/24/2024Q2 2024-$0.26-$0.20+$0.06-$0.20--4/24/2024Q1 2024-$0.27-$0.26+$0.01-$0.26--2/7/2024Q4 2023-$0.25-$0.25--$0.25--10/25/2023Q3 2023-$0.22-$0.23 -$0.01-$0.23--7/26/2023Q2 2023-$0.21-$0.19+$0.02-$0.19--Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW4/26/2023Q1 2023-$0.24-$0.25 -$0.01-$0.25--2/8/2023Q4 2022-$0.23-$0.26 -$0.03-$0.26-- Viking Therapeutics Earnings - Frequently Asked Questions When did Viking Therapeutics announce their last quarterly earnings? Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earning data on Wednesday, October 23, 2024. Learn more on VKTX's earnings history. Did Viking Therapeutics beat their earnings estimates last quarter? In the previous quarter, Viking Therapeutics (NASDAQ:VKTX) reported ($0.22) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.24) by $0.02. Learn more on analysts' earnings estimate vs. VKTX's actual earnings. How can I listen to Viking Therapeutics's earnings conference call? The conference call for Viking Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Viking Therapeutics's conference call transcript? The conference call transcript for Viking Therapeutics's latest earnings report can be read online. Read Transcript How much profit does Viking Therapeutics generate each year? Viking Therapeutics (NASDAQ:VKTX) has a recorded net income of -$85.89 million. VKTX has generated -$0.93 earnings per share over the last four quarters. What is Viking Therapeutics's EPS forecast for next year? Viking Therapeutics's earnings are expected to decrease from ($0.97) per share to ($1.34) per share in the next year. More Earnings Resources from MarketBeat Related Companies Teva Pharmaceutical Industries Earnings Results BeiGene Earnings Results Moderna Earnings Results Viatris Earnings Results Summit Therapeutics Earnings Results Genmab A/S Earnings Results Dr. Reddy's Laboratories Earnings Results Sarepta Therapeutics Earnings Results Catalent Earnings Results Vaxcyte Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW This page (NASDAQ:VKTX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
